We demonstrated that the expression of the FBXO11–ZEB1 axis is strongly associated with the incidence and prognosis of non-small cell lung cancer (NSCLC), the most common type of lung cancer, and has potential as a therapeutic target. Here, ZEB1 is linked to non-small cell lung carcinoma.